Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence

Michela Giustozzi; Melina Verso; Giancarlo Agnelli; Cecilia Becattini

doi:10.1007/s11239-017-1555-4

Related publications

Article2017

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Nicolas Gendron, Nicolas Gendron, Anne Laure Feral‐Pierssens, Anne Laure Feral‐Pierssens, Igor Jurcisin, Igor Jurcisin, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Valérie Bouton, Valérie Bouton, Anne Marie Fischer, Anne Marie Fischer, C Lorenceau-Savale, C Lorenceau-Savale, Agnés Lillo‐Le Louët, Agnés Lillo‐Le Louët, David M. Smadja, David M. Smadja

Article2023

Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases

Sophie Melicine, Sophie Melicine, Paul Billoir, Paul Billoir, Dorothée Faille, Dorothée Faille, Erik Lerkevang Grove, Erik Lerkevang Grove, Minh Patrick Lê, Minh Patrick Lê, Nadine Ajzenberg, Nadine Ajzenberg, David M. Smadja, David M. Smadja, Nicolas Gendron, Nicolas Gendron

Article2020

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Paul Billoir, Julien Brunier, Julien Brunier, Laurence Camoin‐Jau, Laurence Camoin‐Jau, Marie Tuffigo, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Ludovic Suner, Corentin Bonnet, Corentin Bonnet,

Article2018

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal

Nicolas Gendron, Nicolas Gendron, Juliette Gay, Juliette Gay, Marine Lemoine, Marine Lemoine, Pascale Gaussem, Pascale Gaussem, Agnés Lillo‐Le Louët, Agnés Lillo‐Le Louët, David M. Smadja, David M. Smadja

Letter2016

Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database

Albert Trinh-Duc, Albert Trinh-Duc, Agnés Lillo‐Le Louët, Agnés Lillo‐Le Louët, Éric Tellier, Éric Tellier, Thibault Viard, Thibault Viard, Grégoire Le Gal, Grégoire Le Gal, David M. Smadja, David M. Smadja